دورية أكاديمية
أعرض في EDS

Patterns of care for patients with metastatic bone disease in solid tumors: A cross-sectional study from Switzerland (SAKK 95/16).

التفاصيل البيبلوغرافية
العنوان: Patterns of care for patients with metastatic bone disease in solid tumors: A cross-sectional study from Switzerland (SAKK 95/16).
المؤلفون: Mark M; Department of Hematology/Oncology, Kantonsspital Graubünden, Loestrasse 170, 7000 Chur, Switzerland., Thürlimann B; Kantonsspital St. Gallen, St. Gallen, Switzerland., Ribi K; International Breast Cancer Study Group IBCSG (IBCSG), Bern, Switzerland., Schär C; Swiss Group for Clinical Cancer Research (SAKK) Coordinating Center, Bern, Switzerland., Dietrich D; Swiss Group for Clinical Cancer Research (SAKK) Coordinating Center, Bern, Switzerland., Cathomas R; Department of Hematology/Oncology, Kantonsspital Graubünden, Loestrasse 170, 7000 Chur, Switzerland., Zürrer-Härdi U; Kantonsspital Winterthur, Winterthur, Switzerland., von Briel T; Klinik Hirslanden, Zürich, Switzerland., Anchisi S; Hôpital du Valais, Sion, Switzerland., Bohanes P; Centre de Chimiothérapie Anti-Cancéreuse, Lausanne, Switzerland., Blum V; Kantonsspital Luzern, Luzern, Switzerland., von Burg P; Burgerspital Solothurn, Solothurn, Switzerland., Mannhart M; Andreasklinik Cham Zug, Cham, Switzerland., Caspar CB; Kantonsspital Baden, Baden, Switzerland., von Moos R; Department of Hematology/Oncology, Kantonsspital Graubünden, Loestrasse 170, 7000 Chur, Switzerland.
المصدر: Journal of bone oncology [J Bone Oncol] 2019 Dec 16; Vol. 21, pp. 100273. Date of Electronic Publication: 2019 Dec 16 (Print Publication: 2020).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 101610292 Publication Model: eCollection Cited Medium: Print ISSN: 2212-1366 (Print) Linking ISSN: 22121366 NLM ISO Abbreviation: J Bone Oncol Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Amsterdam : Elsevier, c2012-
مستخلص: Background: Bone-targeted agents (BTAs) are widely used in the management of patients with bone metastases from solid tumors, but knowledge of their routine care use and the therapeutic implications remains limited. This non-interventional study aimed to characterize real-world BTA patterns of care in Switzerland.
Materials and Methods: Non-interventional, cross-sectional study involving oncologists from across Switzerland who completed a Treating Physician questionnaire, providing data on their clinical setting and BTA-related practices, and a Patient Characteristics and Treatment questionnaire, providing data on their patients' disease status, risk of bone complications, BTA regimen and related outcomes. Eligible patients were aged ≥ 18 years, with solid tumors and at least one bone metastasis and were receiving routine management at the participating physician's center over the 3-month study period.
Results: A total of 86 oncologists recruited 417 patients from across 18 centers in Switzerland (80% public hospitals; 20% private clinics). The majority of physicians (70.9%) reported prescribing BTAs in line with international guidelines; denosumab was the treatment of choice in 78.5% of patients. BTAs were widely administered (94.2%) according to a 3-4-weekly dosing regimen; 33.7% of physicians reported extending intervals to 12 weeks after an initial 2 years of treatment. Physicians appeared to use clinical judgement, as well as formal risk assessment, to guide treatment for symptomatic skeletal events. No association was seen between either BTA use, or risk of complications, and incidence of skeletal complications. Only 4.3% of patients were reported to be experiencing severe bone pain at the time of the study.
Conclusions: This cross-sectional, non-interventional study found high implementation of guideline-recommended BTA prescribing, good pain control and low incidence of skeletal-related events. Long-term BTA randomized controlled trials have the potential to further optimize routine care outcomes for patients.
(© 2019 The Authors.)
References: Oncologist. 2008 May;13(5):494-502. (PMID: 18515734)
Support Care Cancer. 2011 Nov;19(11):1687-96. (PMID: 21785900)
J Clin Oncol. 2007 Oct 1;25(28):4431-7. (PMID: 17785705)
Clin Ther. 2010 Mar;32(3):426-36. (PMID: 20399982)
J Dent Educ. 2008 Aug;72(8):919-29. (PMID: 18676801)
Cancer. 2003 Oct 15;98(8):1735-44. (PMID: 14534891)
J Dent Res. 2007 Nov;86(11):1022-33. (PMID: 17959891)
J Natl Compr Canc Netw. 2013 Aug;11 Suppl 3:S1-50; quiz S51. (PMID: 23997241)
J Clin Oncol. 2012 Jun 1;30(16):1980-8. (PMID: 22508819)
Am J Clin Oncol. 2013 Oct;36(5):436-42. (PMID: 22781385)
Lancet. 2011 Mar 5;377(9768):813-22. (PMID: 21353695)
Support Care Cancer. 2016 Aug;24(8):3557-65. (PMID: 27022965)
Breast Cancer Res Treat. 2010 Oct;123(3):767-79. (PMID: 20574672)
Oncologist. 2010;15(11):1147-58. (PMID: 21051658)
Mayo Clin Proc Innov Qual Outcomes. 2019 May 27;3(2):235-237. (PMID: 31193884)
N Engl J Med. 2004 Apr 15;350(16):1655-64. (PMID: 15084698)
J Clin Oncol. 2010 Dec 10;28(35):5132-9. (PMID: 21060033)
J Clin Oncol. 2010 Nov 20;28(33):4898-905. (PMID: 20940190)
Curr Pharm Des. 2010;16(11):1262-71. (PMID: 20166976)
J Urol. 2009 Aug;182(2):509-15; discussion 515-6. (PMID: 19524963)
N Engl J Med. 1996 Dec 12;335(24):1785-91. (PMID: 8965890)
J Bone Oncol. 2017 Nov 24;11:1-9. (PMID: 29892519)
Cancer. 1997 Oct 15;80(8 Suppl):1588-94. (PMID: 9362426)
Br J Cancer. 2009 May 19;100(10):1566-74. (PMID: 19401688)
Ann Oncol. 2014 Sep;25 Suppl 3:iii124-37. (PMID: 24782453)
J Bone Oncol. 2013 Feb 09;2(2):70-6. (PMID: 26909273)
Support Care Cancer. 2004 Dec;12(12):852-8. (PMID: 15322969)
Can J Clin Pharmacol. 2004 Spring;11(1):e168-78. (PMID: 15300959)
J Clin Oncol. 2011 Mar 20;29(9):1221-7. (PMID: 21343561)
Support Care Cancer. 2011 Mar;19(3):425-30. (PMID: 20358384)
Ann Oncol. 2008 Dec;19(12):1985-91. (PMID: 18632721)
Lancet Oncol. 2013 Jun;14(7):663-70. (PMID: 23684411)
فهرسة مساهمة: Keywords: BP, bisphosphonate; BTA, bone-targeted agent; Bone metastases; Bone-targeting agents; HRQoL, health-related quality of life; IBCSG, International Breast Cancer Study Group; Non-interventional; Patterns of care; RANKL, receptor activator of nuclear factor kappa-B ligand; RCT, randomized controlled trial; SAKK, Swiss Group for Clinical Cancer Research; SGMO, Schweizerische Gesellschaft für Medizinische Onkologie; SRE, symptomatic skeletal-related event; SSE, symptomatic skeletal event; Skeletal-related event; Symptomatic skeletal events; mCRPC, metastatic castration-resistant prostate cancer
تواريخ الأحداث: Date Created: 20200124 Latest Revision: 20220412
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC6965709
DOI: 10.1016/j.jbo.2019.100273
PMID: 31970055
قاعدة البيانات: MEDLINE
الوصف
تدمد:2212-1366
DOI:10.1016/j.jbo.2019.100273